Oxford Glycosciences

Update on Merger Discussions

Oxford Glycosciences PLC
11 April 2003

The following amendment has been made to RNS No 9260J released at 7.58 today.
The opening sentence should read 'OGS notes the announcement by Sir Christopher
Evans and Alan Goodman regarding their withdrawal of interest in OGS ' and not
as originally shown.  All other details remain unchanged.

Oxford GlycoSciences Plc

11 April 2003

Not for release, publication or distribution in, into or from Australia, Canada
or Japan

                        OXFORD GLYCOSCIENCES PLC ('OGS')

                          UPDATE ON MERGER DISCUSSIONS

OGS notes the announcement by Sir Christopher Evans and Alan Goodman regarding
their withdrawal of interest in OGS. Further to the announcement on 26 March,
2003, OGS has now completed discussions with all interested parties and does not
expect any of these parties to make an offer for OGS.

The OGS Board* will clarify its position in relation to the Celltech offer in
due course.


For further information please contact:

Oxford GlycoSciences Plc                    +44 (0) 1235 208 000
David Ebsworth, Ph.D., Chief Executive Officer

Goldman Sachs International                 +44 (0) 20 7774 1000
Michael Hill

Basil Geoghegan

Phil Raper (Corporate Broking)

Financial Dynamics

UK Media and Investors                     +44 (0) 20 7831 3113
Tim Spratt                                 Mob: +44 (0) 7850 589 166
Melanie Toyne-Sewell                       Mob: +44 (0) 7767 660 040

US Media and Investors                     +1 212 850 5626
Leslie Wolf-Creutzfeldt                    Mob: +1 917 854 4726
Deborah Ardern Jones                       Mob: +1 917 613 1521
Goldman Sachs International is acting for OGS and for no-one else in connection
with this announcement and will not be responsible to any other person for
providing the protections afforded to clients of Goldman Sachs International or
for providing advice in relation to the offer from Celltech, the merger with CAT
or the contents of this announcement.

The directors of OGS accept responsibility for the information contained in this
announcement.  To the best of the knowledge and belief of the directors of OGS
(who have taken all reasonable care to ensure that such is the case), the
information contained in this announcement is in accordance with the facts and
does not omit anything likely to affect the import of such information.*

*Dr Donald Drakeman, a director of OGS, is also the Chief Executive Officer of
Medarex Inc, a competitor of CAT, and therefore did not participate in decisions
of the OGS Board relating to the merger with CAT.  Given this conflict, he has
also not participated and does not propose to participate in discussions
relating to any competing offer for OGS.  Accordingly, Dr Drakeman has abstained
from OGS Board discussions of, and advice to OGS shareholders relating to, the
offer from Celltech and is not taking responsibility for the views or advice of
the Board on the merger with CAT or the offer from Celltech.

Shareholders can obtain a free copy of this and any other documents filed with
the Securities and Exchange Commission at the SEC's website (www.sec.gov).

This announcement does not constitute an offer to sell or invitation to purchase
any securities or the solicitation of any vote or approval in any jurisdiction.

The release, publication or distribution of this announcement in certain
jurisdictions may be restricted by law and therefore persons in such
jurisdictions into which this announcement is released, published or distributed
should inform themselves about and observe such restrictions.

                      This information is provided by RNS
            The company news service from the London Stock Exchange